GoutReMonit GoutNCT07490522
The Remote Monitoring of Gout Feasibility Study in Primary Care
A study testing Patient self-management app 'MinUrinsyregikt' in people with Gout, run by Diakonhjemmet Hospital at 1 site in Norway.
Trial summary
The goal of this feasibility study is to determine the feasibility of a patient self-management app (MinUrinsyregikt) for patients with gout. The primary objectives of the study are: 1. To determine the feasibility of a patient self-management app for patients with gout receiving GP follow-up. 2. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gout
- What is being tested?
- Patient self-management app 'MinUrinsyregikt'
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteNorway
- Study dates
- Apr 2026to Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Patients are eligible to be included in the study only if all the following criteria apply:
- Adults ≥18 years of age at screening
- Patients with a clinical diagnosis of gout
- Serum urate level >360 µmol/L at inclusion
- Indication for urate lowering therapy assessed by medical doctor
- Having a smartphone/tablet
Patients are excluded from the study if any of the following criteria apply:
- Pregnant or breastfeeding
- Contraindication for urate lowering therapy
- Does not understand Norwegian language
- Major co-morbidities (e.g., malignancies, severe chronic kidney disease, severe mental disorders)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Silje Søhus contact
Norway1 site, 1 recruiting
- Recruiting
Diakonhjemmet Hospital
Oslo
Fiona Aanesen, PhD, 47 93699868, fiona.aanesen@diakonsyk.no
Fiona Aanesen, PhD
About this study
Official title: The Self-management App 'MinUrinsyregikt' for Patients With Gout. The ReMonit Gout Feasibility Study in Primary Care
The goal of this feasibility study is to determine the feasibility of a patient self-management app (MinUrinsyregikt) for patients with gout. The primary objectives of the study are:
- To determine the feasibility of a patient self-management app for patients with gout receiving GP follow-up.
- To determine the feasibility of conducting a future randomised controlled trial to test the effectiveness of the app for patients with gout in primary care.
Participants will be asked to test the self-management app for 3 months. Data will be collected from the participants and their GPs.
Read the detailed description
The study is a single-group, decentralized feasibility study over 3 months with pre- and post-intervention measurements and data collections through the app. Patients and GPs will be recruited from primary care throughout Norway. 20-50 adults with a gout diagnosis, serum urate level >360 μmol/L, and an indication for urate lowering therapy will be included in the study.
The patients will receive self-management support from the 'MinUrinsyregikt'-app in addition to usual follow-up from their GP. The study coordinator will provide instructions on how to download and use the app. The patients will register the following information in the app: whether they have tophi, type of urate lowering medication and dose, medical adherence, flares, and the serum urate level from the monthly blood test. The app will provide information about the date for the next blood test, reminders for blood tests and medication, and advice to contact their GP if the urate level is too high. The GPs will be responsible for the medical follow-up of the patients and will not have access to information from the app.
Data will be collected from participants through digital questionnaires at baseline. After 3 months participants and GPs will be asked to answer a digital questionnaire and be invited to participate in semi-structured interviews about their experiences with app-supported follow-up for gout.
- Conditions
- Gout
- Being tested
- Patient self-management app 'MinUrinsyregikt'
- Keywords
- Gout, Feasibility study, E-health, Primary care, Digital health, Urate-lowering Therapy (ULT)
- Medical subject headings
- Gout
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient self-management app 'MinUrinsyregikt'Device
The purpose of the 'MinUrinsyregikt' -app is to support self-management for patients with gout receiving urate lowering therapy. The content of the app reflects current treatment recommendations for gout.
The app includes information videos and texts about gout and gout treatment, registration tools for gout flares, serum urate levels, and medication adherence. The app enables reminder alerts for medications and for blood sampling. After the monthly blood test of serum urate levels, the patients will register this value in the app and respond to two questions to validate the serum urate blood test value. The app will then provide a date for the next blood test and advice the patient to contact their GP if the serum urate level is over the treatment target.
| Study group | Role | What they receive |
|---|---|---|
| Self-management app | Experimental | The patients will receive access to the self-management application 'MinUrinsyregikt' in addition to usual follow-up from their GP. Receives: Device: Patient self-management app 'MinUrinsyregikt' |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptable overall feasibility of the app based on a total evaluation of the secondary endpoints for technical and operational feasibility.
Feasibility criteria:
- No serious and irreversible errors in app
- Mean System Usability Scale score ≥68
- 70% with score ≥5 on a numeric rating scale (0-10) on patient satisfaction with the app
- No serious and irreversible barriers to app-supported follow up experienced by patients or GPs
- No other serious and irreversible problems with the app
Measured: 3 months
Acceptable overall trial feasibility based on the total evaluation of the secondary endpoints for trial feasibility.
Feasibility criteria:
- Recruitment rate ≥50% of eligible patients
- Withdrawal rate ≤20% of included patients
- ≥90% of the patients register their sUA level in the app throughout the study
- ≥90% of the patients answer baseline and 3 months questionnaires
- No serious and irreversible risks or challenges that could hinder a successful clinical evaluation of the app in a large randomised controlled trial
Measured: 3 months
Secondary outcomes (16)
Technical feasibility: Patient-reported errors in app
Number and type of technical errors in app reported by patients through the app and in questionnares at 3 months.
Measured: 3 months
Technical feasibility: Patient-reported software performance and functionality
Patient experiences of app performance, functionality and ease of use. From semi-structured interviews.
Measured: 3 months
Technical feasibility: Patient-reported software usability
Patient reported software usability, measured with The System Usability Scale (SUS), sum score 0-40 converted into 0-100, 100 = best score. From questionnaire at 3 months.
Measured: 3 months
Technical feasibility: Patient-reported satisfaction with the app
Patient satisfaction with the app, measured with one item rated on a 0-10 numeric rating scale, ranging from 'very dissatisfied' (0) to 'very satisfied' (10), from questionnaire at 3 months.
Measured: 3 months
Technical feasibility: Patient-repoted benefits and disadvantages of the app
Patients perceived benefits and disadvantages with the app collected from semi-structured interviews.
Measured: 3 months
Operational feasibility: Patients' training requirements
Patient evaluation of the demo films and instruction manual. From semi-structured interviews.
Measured: 3 months
Operational feasibility: GP and patient-reported barriers and facilitators of app-supported gout follow-up
Barriers and facilitators of app-supported gout follow-up experienced by patients and GPs. From semi-structured interviews and questionnaires at 3 months.
Measured: 3 months
Operational feasibility: Patient satisfaction with the follow-up care
Participant satisfaction with the care, measured by one item from The Nordic Patient Experiences Questionnaire, with five point response options ranging from "Very satisfied" to "Very dissatisfied" from questionnaire at 3 months.
Measured: 3 months
Trial feasibility: Number of eligible patients per month and recruitment rate
Number of patients screened, number of eligible patients, and the number of consenting patients every month, including information about how the patient was recruited. From identification and recruitment logs completed during the recruitment period and questionnaires at 3 months.
Measured: 3 months
Trial feasibility: Patient dropout
Number of patients that withdraw from the study, reasons for dropout (if provided). From logs completed during the study period.
Measured: 3 months
Trial feasibility: Patients' app use
Number of videos watched, registration of serum urate levels, medication adherence and flares in the app. From back-end data from the app and semi-structured interviews with patients.
Measured: 3 months
Trial feasibility: Barriers and facilitators to study participation for patients and GPs
Barriers and facilitators for study participation experienced by patients and GPs, from semi-structured interviews.
Measured: 3 months
Trial feasibility: Provision of blood-test results from GPs
Number of GPs providing blood test results and number of missing blood-test results from GPs, from questionnaires at 3 months.
Measured: 3 months
Trial Feasibility: Serum urate level registrations in the app
Number of correct, incorrect and missing serum urate level registrations in the app. Urate level registrations from app and urate levels from blood tests provided by GPs at 3 months.
Measured: 3 months
Trial feasibility: Patients' response to questionnaires
Response-rate to baseline questionnaire. Response-rate to 3-month questionnaire.
Measured: 3 months
Trial feasibility: Adverse events
The number of adverse events (AE), serious adverse events (SAE), adverse device effects (ADE) and serious adverse device effects (SADE). From questionnaires at 3-months to patients and GPs.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2026
- Study startApr 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GoutStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Diakonhjemmet Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The Dam Foundation, The Norwegian Rheumatism Association, REMEDY - Center for treatment of Rheumatic and Musculoskeletal Diseases
- Responsible party
- Principal investigator, Fiona Aanesen, Diakonhjemmet Hospital
- Investigators
- Fiona Aanesen, Principal investigator, Diakonhjemmet Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07490522
- Sponsor's protocol ID
- 966720
- Other IDs
- 25/03734
- Acronym
- ReMonit Gout
- Status last verified
- Apr 2026
- First submitted
- 6 Mar 2026
- Last updated
- 30 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No